Facebook
Twitter
LinkedIn
Forward
Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study
Instructions
Click the red REGISTER button to pay the $10 fee and take the posttest.
Click here to return to the PCC CME article.
Overview
Certain antipsychotics are known to increase weight and the risk for diabetes. Could some medications for diabetes promote not only glycemic control but also weight loss in patients taking antipsychotics? In this CME activity, review the results of a small retrospective study.
Read the whole article at psychiatrist.com here:
Glucagon-Like Peptide Analogs Are Superior for Diabetes and Weight Control in Patients on Antipsychotic Medications: A Retrospective Cohort Study
© Copyright 2020 Physicians Postgraduate Press, Inc.
Target Audience
Primary care clinicians
Learning Objectives
Monitor patients with severe mental illness who are taking antipsychotic medications for metabolic syndrome and diabetes so that treatment can be implemented as appropriate to minimize adverse cardiovascular outcomes
CME Background
Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.
CME Objective
After studying this article, you should be able to:
- Monitor patients with severe mental illness who are taking antipsychotic medications for metabolic syndrome and diabetes so that treatment can be implemented as appropriate to minimize adverse cardiovascular outcomes
Statement of Need and Purpose
Prescribers are advised to monitor patients for metabolic side effects of antipsychotics and appropriately treat obesity, dyslipidemia, and diabetes. Diabetes medications differentially impact weight and cardiovascular outcomes. Clinicians need education about studies of the efficacy of newer medications in diabetic patients who are taking antipsychotics, with or without antidepressants. Too few clinicians follow guidelines for monitoring metabolic risks in patients taking antipsychotics; education about newer interventions may encourage their increased assessment and treatment.
Release, Expiration, and Review Dates
This educational activity was published in February 2020 and is eligible for AMA PRA Category 1 Credit™ through February 28, 2022. The latest review of this material was January 2020.
Disclosure of off-label usage
The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this article.
Funding/support
None.
Previous presentation
These data were presented as a published abstract at the Annual Meeting of the American Diabetes Association; June 22–26, 2018; Orlando, Florida.
Acknowledgments
The authors wish to thank Stephen R. Hammes, MD, PhD, and Steven D. Wittlin, MD, for their critical advice and review of the manuscript. Drs Hammes and Wittlin report no conflicts of interest related to the subject of this article.
Faculty Affiliation
Lauren T. Perlis, MD
Department of Family Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
J. Steven Lamberti, MD
Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York
Susanne U. Miedlich, MD*
Division of Endocrinology and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York
*Corresponding author: Susanne U. Miedlich, MD, Division of Endocrinology and Metabolism, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 693, 601 Elmwood Ave, Rochester, NY 14642 ([email protected]).
Financial Disclosure
All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Larry Culpepper, MD, MPH, Editor in Chief of The Primary Care Companion for CNS Disorders, has been a consultant for Acadia, Allergan, Eisai, Merck, Supernus, and Takeda; has been a stock shareholder of M-3 Information; and has received royalties from UpToDate and Oxford University Press. No member of the CME Institute staff reported any relevant personal financial relationships.
Drs Perlis, Lamberti, and Miedlich have no personal affiliations or financial relationships with any commercial interest to disclose relative to this article.
Accreditation Statement
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation